carmustine

P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027

CWI did not significantly improve OS or SAR in recurrent GBM patients. However, younger age, MGMT methylation, smaller residual tumor volume, and later recurrence were linked to better survival outcomes, underscoring their prognostic importance.

Additionally,TDG expression was positively associated with tumor mutational burden (P<0.001),microsatellite instability (P=0.045),mutant-allele tumor heterogeneity (P=0.001),and tumor neoantigens (P<0.001) in lung adenocarcinoma.In lung adenocarcinoma,the expression of TDG was notably elevated in the tumor tissue compared with that in adjacent normal tissue (P<0.001).Male patients exhibited higher levels of TDG expression than female patients (P=0.002),and smokers demonstrated higher TDG expression than non-smokers (P<0.001).Furthermore,TDG expression was correlated with smoking cessation duration (P=0.014).Positive correlations were observed for TDG expression with both clinical T stage (P=0.003) and distant metastasis (P=0.012),while a negative correlation was found with patient prognosis (P=0.030).Furthermore,TDG emerged as an independent prognostic factor for lung adenocarcinoma.In vitro experiments revealed that silencing TDG inhibited the proliferation and migration of lung adenocarcinoma cells (both P<0.05).A correlation analysis between TDG-related genes and target kinases revealed that in lung adenocarcinoma,genes encoding aurora kinase A,cyclin-dependent kinase 2 and other enzymes exhibited positive correlations with TDG expression (all P<0.001).Furthermore,TDG expression demonstrated positive correlations with functional states including the cell cycle,DNA damage,and DNA repair processes (all P<0.001).In addition,the expression of TDG was correlated with the efficacy of treatment in the first course in clinical patients (P=0.007).Specifically,TDG expression levels were higher in the progressive disease group than in the stable disease group (P=0.016),and lower in the complete remission group than in the progressive disease group (P<0.001).Additionally,elevated TDG expression was associated with enhanced resistance to oxaliplatin (P<0.001),carmustine (P<0.001),and olaparib (P=0.004). Conclusion TDG serves as a potential prognostic biomarker,an immunotherapeutic target,and a oncogene in pan-cancer,with particular significance in lung adenocarcinoma.

P2, N=20, Recruiting, Zhejiang Cancer Hospital | Not yet recruiting --> Recruiting

P1/2, N=70, Terminated, VBI Vaccines Inc. | Recruiting --> Terminated; VBI Bankruptcy

P1, N=25, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

P2, N=50, Recruiting, Chinese PLA General Hospital | Trial completion date: Jun 2023 --> Jun 2031 | Trial primary completion date: Jun 2022 --> Jun 2030

High TRPRS was associated with diminished cytotoxic T-cell infiltration and predicted resistance to multiple therapeutics-including cisplatin, carmustine, gefitinib, buparlisib, and afatinib. Functional assays demonstrated that IFNGR2 knockdown suppressed glioma cell proliferation and attenuated NF-κB signaling, underscoring its role as a key driver within the TRP network. TRPRS provides a robust, biologically grounded tool for simultaneous prognostication and therapy guidance in GBM, highlighting TRP signaling as a therapeutic vulnerability.

P2, N=20, Not yet recruiting, Zhejiang Cancer Hospital

P1, N=20, Recruiting, Washington University School of Medicine | Trial completion date: Nov 2026 --> Jun 2031 | Trial primary completion date: Aug 2026 --> Mar 2031

P2, N=49, Recruiting, VIVUS LLC | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

P2, N=227, Completed, International Extranodal Lymphoma Study Group (IELSG) | N=126 --> 227